Definition and epidemiology
HPPD is a persisting, drug-induced perceptual disorder characterized by continuous or recurring visual disturbances that resemble the perceptual effects of hallucinogen intoxication, occurring after the acute effects of the drug have resolved and in the absence of current intoxication or another medical explanation.
It is classified in DSM-5-TR as hallucinogen persisting perception disorder, and in ICD-10 under F16.7, within the hallucinogen-related disorders.
- True prevalence is unknown and likely underestimated because many affected individuals do not seek care or are misdiagnosed.
- Most commonly associated with LSD, but also reported after psilocybin, MDMA, cannabis, and other serotonergic hallucinogens.
- Onset is typically within days to weeks of hallucinogen use, though some cases follow a single exposure.
- Affects a small minority of hallucinogen users; the exact proportion that develops persistent symptoms versus transient post-use visual phenomena is not well established.
- No clear sex predominance; usually presents in adolescents or young adults, consistent with peak recreational drug use ages.
- HPPD symptoms are continuous/near-continuous, unlike episodic drug flashbacks.
- Reality testing is intact—this excludes a primary psychotic disorder.
- LSD is the hallucinogen most commonly implicated.
- Visual snow, trailing (palinopsia), and halos are classic symptoms.
- Diagnosis is clinical; rule out ophthalmologic, neurologic, and migrainous causes.
- Comorbid anxiety/depression often drive the functional impairment more than visual symptoms.
- Clonidine and lamotrigine are used off-label with limited evidence.
- Cannabis use can trigger or worsen HPPD symptoms even without further hallucinogen use.
Etiology and risk factors
The exact mechanism is unknown, but leading hypotheses center on persistent changes in visual processing circuitry following serotonergic hallucinogen exposure.
- Prior hallucinogen use, especially LSD, is the defining risk factor; multiple or high-dose exposures may increase risk, though HPPD has occurred after a single use.
- Underlying anxiety or mood disorders may increase vulnerability and worsen symptom perception.
- Concurrent cannabis or other substance use can exacerbate symptoms.
- Genetic predisposition is suspected but not well characterized.
- Not related to current drug use, intoxication, or withdrawal; by definition symptoms occur after cessation.
Pathophysiology
The leading theory implicates dysfunction of inhibitory GABAergic interneurons in the visual cortex, leading to disinhibition of visual processing pathways. Serotonergic hallucinogens act primarily as 5-HT2A receptor agonists, and persistent downstream changes in cortical excitability are thought to underlie ongoing symptoms after the drug itself is gone.
- Functional imaging studies (limited, small samples) have suggested altered activity in visual association areas and the lateral geniculate nucleus pathway.
- The disorder is thought to represent a persistent neurophysiologic change rather than ongoing pharmacologic drug effect, which distinguishes it from intoxication or flashback phenomena.
- Symptoms are purely perceptual (visual processing abnormality), not psychotic—patients retain full insight that what they see is not real.
Clinical features
The hallmark is persistent or recurring visual disturbances resembling those experienced during hallucinogen intoxication, but occurring without current drug use.
Common visual symptoms
- Visual snow: static-like graininess across the visual field
- Trailing phenomena (palinopsia): afterimages or trails following moving objects
- Halos around lights, especially at night
- Geometric pseudo-hallucinations or pattern distortions
- Enhanced awareness of floaters or entoptic phenomena
- Photophobia and difficulty with night vision
- Perceived intensification of colors or afterimages of color
Key features that distinguish HPPD
- Symptoms are usually continuous or near-continuous, not episodic like classic drug flashbacks
- Insight is preserved—patients recognize the visual disturbances are not real, distinguishing HPPD from a psychotic disorder
- Symptoms often wax and wane in intensity, worsened by fatigue, stress, low lighting, or re-exposure to any psychoactive substance (including cannabis or alcohol)
- Associated anxiety, depersonalization, or depression frequently accompany the visual symptoms and can be more functionally impairing than the visual symptoms themselves
- Duration is variable: can last weeks to years; some cases become chronic
Diagnosis
HPPD is a clinical diagnosis of exclusion based on history and mental status examination; there is no confirmatory laboratory or imaging test.
DSM-5-TR criteria (summarized)
- Reexperiencing of perceptual symptoms that occurred while intoxicated with a hallucinogen (e.g., geometric hallucinations, visual snow, trails, halos)
- Symptoms cause clinically significant distress or impairment
- Symptoms are not due to another medical condition and are not better explained by another mental disorder or delirium
Workup
- Detailed substance use history, including timing of hallucinogen use relative to symptom onset
- Ophthalmologic examination to exclude ocular pathology (e.g., vitreous disease, retinal disorders)
- Neurologic examination and consideration of neuroimaging (MRI brain) if atypical features, focal deficits, or progressive course to exclude structural lesions
- Screen for migraine with aura, as visual symptoms can overlap
- Mental status exam confirming intact reality testing (no delusional interpretation of the visual phenomena)
- Urine toxicology may be used to exclude ongoing substance use but is not diagnostic of HPPD itself
Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| Migraine with aura | Episodic, often unilateral, accompanied by headache; visual symptoms typically last minutes, not continuous |
| Visual snow syndrome | Can occur without any hallucinogen history; considered a distinct entity, overlaps clinically with HPPD |
| Psychotic disorder (schizophrenia) | True hallucinations with impaired insight/reality testing; often other psychotic features (delusions, disorganized thought) |
| Occipital lobe seizure | Brief, stereotyped visual phenomena, may have other seizure semiology, abnormal EEG |
| Posterior cortical atrophy / neurodegenerative disease | Progressive course, older patients, other cognitive deficits |
| Ophthalmologic disease (vitreous floaters, retinal detachment) | Confined to one eye or visual field defect, abnormal fundoscopic exam |
| Charles Bonnet syndrome | Occurs with significant vision loss, typically in older adults |
| Substance intoxication/withdrawal | Temporally linked to active use; HPPD occurs after cessation |
Management
There is no FDA-approved treatment specific to HPPD, and management is largely supportive, based on case reports and small case series rather than randomized controlled trials.
General principles
- Complete abstinence from hallucinogens and, often, from cannabis and other psychoactive substances, which can trigger or worsen symptoms
- Patient education and reassurance that the condition, while distressing, is not indicative of a psychotic disorder and reality testing is intact
- Address comorbid anxiety and depression, which often drive the distress more than the visual symptoms themselves
- Cognitive behavioral therapy (CBT) can help patients cope with symptom-related anxiety and reduce hypervigilance to visual phenomena, which may paradoxically worsen perceived severity
Pharmacologic options (limited evidence, used off-label)
- Clonidine: an alpha-2 agonist reported to reduce symptom intensity in some cases
- Lamotrigine: an anticonvulsant used in case reports with variable benefit
- Benzodiazepines (e.g., clonazepam): may reduce anxiety and perceived symptom intensity but carry dependence risk with long-term use
- SSRIs: used to treat comorbid anxiety/depression; caution advised as some SSRIs have been reported to worsen HPPD symptoms in isolated cases
- Avoid substances that can precipitate or worsen symptoms, including cannabis, stimulants, and further hallucinogen exposure
There is no single internationally endorsed guideline algorithm for HPPD given the rarity and limited evidence base; treatment choices should be individualized and guided by symptom severity and comorbidity.
Complications and prognosis
- Course is variable: many cases gradually improve or resolve over months, but some patients experience a chronic, persistent course lasting years
- Functional impairment often relates more to secondary anxiety, depression, and avoidance behaviors than to the visual symptoms themselves
- Risk of misdiagnosis as a primary psychotic disorder, leading to inappropriate antipsychotic treatment, if clinicians fail to recognize preserved insight
- Continued use of hallucinogens or other psychoactive substances (notably cannabis) can exacerbate or prolong symptoms
- No evidence that HPPD progresses to a primary psychotic illness in the absence of other risk factors
- Early recognition, abstinence, and treatment of comorbid mood/anxiety symptoms are associated with better functional outcomes
HALO: Hallucinogen history, Awareness (insight) preserved, Lasting/continuous visual symptoms, Ophthalmologic/neurologic causes excluded.
Practice questions
1. A 22-year-old man presents with 3 months of persistent visual disturbances, describing constant 'static' across his vision and trails following moving objects, which began a week after using LSD at a music festival. He has not used any drugs since. He is anxious about the symptoms but states, 'I know it's not real, it's just really distracting.' Neurologic and ophthalmologic exams are normal. Which of the following is the most likely diagnosis?
2. A 19-year-old woman with a history of recreational LSD use 2 months ago presents with ongoing visual halos and light sensitivity. She has intact insight into the unreality of her symptoms. Which additional feature would most strongly suggest an alternative diagnosis of migraine with aura rather than HPPD?
3. A patient with suspected HPPD and significant associated anxiety is being considered for pharmacologic treatment. Which of the following best reflects current evidence-based management of this condition?
Frequently asked questions
What causes hallucinogen persisting perception disorder?
HPPD is caused by prior use of a hallucinogen, most commonly LSD, that leads to lasting changes in visual processing circuits in the brain. The exact mechanism is unclear but likely involves disinhibition of visual cortex pathways after serotonergic receptor stimulation. It is not caused by ongoing drug use—symptoms persist after the substance has fully left the body.
What are the first symptoms of HPPD?
The first symptoms are usually visual disturbances resembling the drug's intoxication effects, such as visual snow, trailing images behind moving objects, halos around lights, and geometric pattern distortions. These typically begin within days to weeks of hallucinogen use and are often accompanied by anxiety about the symptoms themselves.
How is HPPD diagnosed?
HPPD is diagnosed clinically based on a history of hallucinogen use, persistent visual symptoms resembling intoxication effects, and preserved insight that the perceptions are not real. Ophthalmologic and neurologic exams are used to exclude other causes like retinal disease, migraine, or seizures, since there is no specific lab or imaging test for HPPD.
Is HPPD curable?
HPPD is not reliably curable, but many cases improve or resolve gradually over months with abstinence from hallucinogens and other psychoactive substances. Some patients have a chronic, persistent course lasting years. Treatment focuses on symptom management, reassurance, and addressing associated anxiety or depression rather than a definitive cure.
HPPD vs flashback — what is the difference?
A classic hallucinogen flashback is a brief, episodic reexperience of intoxication-like perceptions that comes and goes, while HPPD involves continuous or near-continuous visual symptoms that persist over an extended period. Both occur after hallucinogen use, but HPPD is a sustained perceptual disorder rather than an intermittent recurrence.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F16.7
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.